Common questions about Marlissa (FAQ)
Q: What hormones are in Marlissa, and what is their strength?
The official product information states that each active tablet contains two hormones: levonorgestrel (a progestin) and ethinyl estradiol (an estrogen). This combination is dosed at 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol per active pill.
Q: Is Marlissa considered a low-dose or high-dose combined oral contraceptive?
This combination oral contraceptive contains 30 \mug of ethinyl estradiol. Official sources categorize pill strengths based on this component, and this level is generally classified as a low-dose oral contraceptive.
Q: What is the difference between Marlissa and the brand-name pill Levora?
Regulatory agencies confirm that Marlissa is a generic equivalent of the brand-name pill. Generic drugs contain the exact same active ingredients (hormones and dosage) as the brand name, and carry the same risks and benefits. However, they may differ in their inactive ingredients, such as coloring or fillers.
Q: Are all generic versions of Marlissa exactly the same in every way?
All generic versions of the same drug must contain the same active ingredients at the same strength to ensure they are therapeutically equivalent. Any differences are limited to the inactive ingredients, such as the coatings, colors, or fillers used in the tablet.
Q: How does Marlissa work to prevent pregnancy, in simple, non-clinical terms?
The hormones in this medication primarily work by suppressing the body's natural cycle to stop the release of an egg from the ovary, which is called ovulation. The progestin component also works locally by thickening cervical mucus, which helps to block sperm, and by altering the lining of the uterus.
Q: Does Marlissa have any uses besides just preventing pregnancy?
Regulatory and clinical information indicates that Marlissa may be associated with certain non-contraceptive benefits. This includes helping to make the menstrual cycle more regular and predictable, potentially decreasing blood loss and painful periods, and may also be used in the treatment of acne.
Q: What is the difference between Marlissa and a progestin-only birth control pill?
Marlissa is officially a combination pill because it contains two synthetic hormones: an estrogen and a progestin. A progestin-only pill, sometimes called the 'mini-pill,' contains only the progestin hormone and no estrogen component.
Q: Is there a known connection between Marlissa use and feeling bloated or gassy?
Official documents report that both bloating and stomach cramping are possible adverse effects. These issues are often related to fluid retention, which is also a reported potential effect of the medication.
Q: What are the official warning signs of a rare, serious blood clot risk associated with Marlissa?
Official product warnings specify the symptoms that may indicate a serious, rare blood clot. These include sudden severe headaches, unexplained loss of vision, chest pain or discomfort, and pain or swelling in the leg or foot.
Q: What kind of changes in appetite are reported by users of Marlissa?
Official adverse event reports indicate that changes in appetite are a possibility when taking this medication. Both increased appetite and decreased appetite have been reported as adverse effects.
Q: Which medications are known to significantly reduce the effectiveness of Marlissa?
Official labeling indicates that certain substances can reduce the effectiveness of this contraceptive by speeding up the breakdown of its hormones in the body. This includes some anticonvulsant medications, certain antibiotics such as rifampin, and the herbal product St. John's Wort.
Q: Does taking common antibiotics, like penicillin or amoxicillin, interact with Marlissa?
Regulatory documents suggest that certain common antibiotics, including specific penicillins and tetracyclines, may interact with this oral contraceptive.
Q: Is there an interaction risk between Marlissa and grapefruit or grapefruit juice?
Official drug interaction listings include grapefruit juice as a substance that may interact with this medication.
Q: Is Marlissa known to interact with common pain relievers like acetaminophen or ibuprofen?
Regulatory documents note that the common pain reliever acetaminophen (as well as Ascorbic Acid) can increase the systemic concentration of the estrogen component in the body.
Q: How might Marlissa affect women who have a history of migraines?
This medication is strictly contraindicated (prohibited) for women who experience migraine headaches with aura. It is also contraindicated for women over the age of 35 who experience any type of migraine headache.
Q: What should be done if vomiting or severe diarrhea occurs shortly after taking a Marlissa tablet?
If vomiting or severe diarrhea occurs for more than one or two days, the absorption of the hormones may be compromised. Regulatory guidance notes that a back-up contraceptive method may be considered for the next 7 days in this situation.
Q: How quickly does Marlissa start providing protection against pregnancy after the first pill?
How quickly protection begins depends on the starting schedule. If the first pill is taken on Day 1 of the menstrual period, additional contraception is not needed. If the pill is started on a Sunday or at any other time, an additional non-hormonal method is generally recommended for the first seven consecutive days.
Q: What is the difference between "perfect use" and "typical use" effectiveness for Marlissa?
Clinical studies show that the pill is over 99% effective when used perfectly, meaning every tablet is taken correctly and on time. However, the 'typical use' effectiveness is cited at approximately 91%, accounting for real-world errors like missed pills.
Q: What happens to the menstrual cycle and bleeding pattern while taking Marlissa?
Marlissa is designed to make the menstrual cycle more regular and predictable. A scheduled withdrawal bleed, similar to a period, is expected during the seven days of inactive pills. Irregular bleeding, or spotting, is a commonly reported side effect that may occur while taking the active pills.
Q: Is it acceptable to skip the seven pink 'inactive' pills in a Marlissa pack to avoid a period?
The standard 28-day regimen requires taking the seven inactive pills. Skipping the inactive pills to avoid a period is not part of the standard FDA-approved dosing schedule for this specific pack.
Q: Can Marlissa be used immediately after a miscarriage or abortion?
After a first-trimester abortion or miscarriage, starting the pill immediately is generally permitted. After a second-trimester event, starting is generally not recommended until 4 weeks later due to a temporary increased risk of blood clots.
Q: How long does it usually take for a person's natural menstrual cycle and fertility to return after stopping Marlissa?
Official information suggests that fertility typically returns relatively quickly. It is often noted that waiting for one natural menstrual cycle to occur after stopping the medication can aid in conception planning.
Q: Why is it important to take Marlissa at the exact same time every day?
Taking the tablet at the same time every day is important for achieving maximum contraceptive effectiveness. The product information specifies that intervals must not exceed 24 hours.
Q: What is the difference between breakthrough bleeding and a regular period while on Marlissa?
Breakthrough bleeding or spotting is defined as unexpected bleeding that happens while a person is taking the active hormone pills. The regular period, or withdrawal bleed, is the expected bleeding that happens during the seven inactive pill days.
Q: Does Marlissa have a risk classification for use during pregnancy, in case a pill is accidentally taken while pregnant?
Official documents state that pregnancy is a formal contraindication for this medication. This means there is no reason to continue using combination oral contraceptives during pregnancy.
Q: What is the purpose of the seven pink 'inactive' pills in the Marlissa pack?
The seven inactive pills are included in the 28-day pack for two reasons: to maintain the routine of taking one pill daily and to allow a scheduled withdrawal bleed to occur.
Q: Has the effectiveness and safety of Marlissa been proven in large-scale clinical research?
Yes, the high efficacy and safety of similar levonorgestrel/ethinyl estradiol formulations have been demonstrated in large-scale clinical studies. Official information indicates a failure rate of less than 1% when used consistently and correctly.
Q: How often should a person expect to have a follow-up visit or physical exam while using Marlissa?
Regulatory documents indicate that regular monitoring and check-ups are generally recommended. This is done to assess the continued suitability and safety of the medication, particularly in the presence of risk factors for conditions like hypertension or diabetes.
Q: How does Marlissa affect the severity of menstrual cramps?
Official patient labeling suggests that this medication may help to decrease the severity of painful periods, a condition known as dysmenorrhea.
Q: Does Marlissa affect cholesterol or lipid levels in the body?
Official warnings note that the medication may have adverse effects on carbohydrate and lipid (cholesterol) metabolism. It is generally contraindicated for women with uncontrolled dyslipidemias (abnormal lipid levels).
Q: Are there any reported long-term effects of Marlissa on bone density?
The estrogen component of the pill has been noted in product information to potentially affect bone density, which is a factor noted particularly in the context of long-term use.
Q: What is the active hormone dose of ethinyl estradiol in Marlissa?
The active dose of the synthetic estrogen component, ethinyl estradiol, in each active tablet is 0.03 mg (or 30 \mug). This level is generally classified in the low-dose range for combination pills.
Q: What is the documented risk of developing melasma or skin discoloration while on Marlissa?
Melasma, which appears as patchy brown or dark discoloration of the skin, is a reported adverse event associated with the use of this pill. The frequency of this skin issue is listed as 'frequency not reported' in postmarketing experience.
